52800 (2021). Chris Bishop to the Minister for COVID-19 Response

52800 (2021). Chris Bishop to the Minister for COVID-19 Response: In relation to these minutes from the COVID-19 Vaccine Technical Advisory Group of 21 September 2021, "However, greater emphasis is needed on the benefits provided by longer dosing intervals, with CV TAG expressing concern that intervals of 3 weeks were becoming more common in Auckland’s outbreak", what was the concern from CV TAG around intervals of 3 weeks becoming more common in Auckland’s outbreak?

Hon Chris Hipkins: I am advised that data had emerged that longer intervals between doses of the Pfizer vaccine produced higher antibody titres. In August 2021, the standard gap between first and second doses of the Pfizer vaccine was extended from 3 to 6 weeks to ensure that partial protection was given to a larger number of people faster. However, a shorter time between the doses was still recommended in some cases, such as when people are at higher risk of contracting COVID-19, or for those who have a specific clinical treatment plan. Since August, the Delta outbreak has increased the risk of contracting COVID-19 for everyone in New Zealand. Because of this increased risk, we are now advising every eligible individual in New Zealand to consider a shorter gap of 3 weeks between doses. Reducing this gap means more people can be fully vaccinated sooner, increasing New Zealand's community immunity.